Bioimaging of tumor markers using both engineered lectins and antibodies
| Project/Area Number |
21390173
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
YAMAMOTO Kazuo 東京大学, 大学院・新領域創成科学研究科, 教授 (20174782)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2011: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2010: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2009: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Keywords | レクチン / 腫瘍マーカー / がん糖鎖抗原 / イメージング |
|---|
| Research Abstract |
It is crucial to identify biomarkers that are highly selective and sensitive in the diagnosis of cancers. We aimed to make a diagnosis platform using both antibodies and engineered lectins for detecting increased glycoprotein expression and alteration of sugar moieties accompanied with tumor progression, respectively. Two kinds of methods were applied to screen engineered lectins from randomly substituted lectin library, and several clones specific for tumor-associated glyco-antigens were obtained. Some cancer cells and specimens clearly stained with Fc-fusion proteins of these engineered lectins, which indicated that it would be a selective tool for diagnosis along with a specific antibody.
|
Report
(4 results)
Research Products
(12 results)
-
-
-
-
[Journal Article] The sugar-binding ability of human OS-9 and its involvement in ER-associated degradation2010
Author(s)
K. Mikami, D. Yamaguchi, H. Tateno, D. Hu, S. Qin, N. Kawasaki, M. Yamada, N. Matsumoto, J. Hirabayashi, Y. Ito, K. Yamamoto.
-
Journal Title
Glycobiology
Volume: 20
Pages: 310-321
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
